RxDoctor Payments Data

Lauren Cadish, MD

Urogynecology and Reconstructive Pelvic Surgery · Santa Monica, CANPI 1104089655

Payments from drug & device makers

$1,618in general payments, 2019–2025

Across 30 payments — averaging $53.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$455
  • Medtronic$417
  • Boston Scientific$244
  • AbbVie$214
  • Coloplast$149
  • Bluewind Medical$84
  • plus $56 from 2 others

What the payments were for

  • Food & beverage$1,618100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Axonics, Inc.7$455
Medtronic(2 entities)5$417
Boston Scientific2$244
AbbVie(2 entities)10$214
Coloplast2$149
Bluewind Medical2$84
Organogenesis Inc.1$36
Smith+Nephew1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,618 in reported general payments places this provider in the 20th percentile of 130 urogynecology and reconstructive pelvic surgery providers in California.

See all urogynecology and reconstructive pelvic surgery providers in California

Medicare billing

Part B allowed, 2024
$105,499
Medicare patients
210
Services billed
1,666

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron257$186,429
MyrbetriqMirabegron215$143,969
Estradiol104$8,057
Methenamine Hippurate76$5,800
EstringEstradiol11$5,666
YuvafemEstradiol27$3,892
Cefpodoxime Proxetil23$649
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst37$249
Clobetasol Propionate11$134
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim34$116

Paid to pharmacies, not to this prescriber.

Other urogynecology and reconstructive pelvic surgery in Santa Monica

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →